anle138b
Multiple System Atrophy (MSA)
About Modag
Modag is a private, preclinical-stage biotech developing a novel class of small molecule therapeutics targeting the underlying pathology of neurodegenerative diseases. The company's core technology is based on proprietary anle138b and related compounds, which are designed to inhibit the aggregation of pathological proteins like alpha-synuclein. As a pre-revenue entity, Modag's success hinges on advancing its lead candidate through clinical trials to demonstrate proof-of-concept in humans. The company operates in a highly competitive but potentially lucrative market, aiming to address the root cause of diseases such as Multiple System Atrophy (MSA) and Parkinson's disease.
View full company profileAbout Modag
Modag is a private, preclinical-stage biotech developing a novel class of small molecule therapeutics targeting the underlying pathology of neurodegenerative diseases. The company's core technology is based on proprietary anle138b and related compounds, which are designed to inhibit the aggregation of pathological proteins like alpha-synuclein. As a pre-revenue entity, Modag's success hinges on advancing its lead candidate through clinical trials to demonstrate proof-of-concept in humans. The company operates in a highly competitive but potentially lucrative market, aiming to address the root cause of diseases such as Multiple System Atrophy (MSA) and Parkinson's disease.
View full company profile